{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Aurora&page=21&state=Colorado",
    "query": {
      "state": "Colorado",
      "city": "Aurora",
      "page": 21
    },
    "page_size": 10
  },
  "pagination": {
    "page": 21,
    "page_size": 10,
    "total_count": 7437,
    "total_pages": 744,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Aurora&page=22&state=Colorado&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Aurora&page=20&state=Colorado&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T15:47:10.999Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02135042",
      "title": "Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "EBV Infection",
        "Stage II Nasopharyngeal Carcinoma AJCC v7",
        "Stage III Nasopharyngeal Carcinoma AJCC v7",
        "Stage IVA Nasopharyngeal Carcinoma AJCC v7",
        "Stage IVB Nasopharyngeal Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Clinical Observation",
          "type": "OTHER"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "NRG Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 924,
      "start_date": "2014-07-01",
      "completion_date": "2034-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-03T15:47:10.999Z",
      "location_count": 197,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Auburn, California + 150 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Auburn",
          "state": "California"
        },
        {
          "city": "Berkeley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02135042"
    },
    {
      "nct_id": "NCT01701570",
      "title": "Barriers to Physical Activity in People With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Placebo Attention Control",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Supervised Exercise Training",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "50 Years to 70 Years"
      },
      "enrollment_count": 35,
      "start_date": "2012-04",
      "completion_date": "2018-08",
      "has_results": false,
      "last_update_posted_date": "2022-10-14",
      "last_synced_at": "2026-11-03T15:47:10.999Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01701570"
    },
    {
      "nct_id": "NCT04333823",
      "title": "Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin 5mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Hospital for Sick Children",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "12 Years to 18 Years"
      },
      "enrollment_count": 100,
      "start_date": "2020-12-11",
      "completion_date": "2024-05",
      "has_results": false,
      "last_update_posted_date": "2023-11-21",
      "last_synced_at": "2026-11-03T15:47:10.999Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04333823"
    },
    {
      "nct_id": "NCT00043459",
      "title": "Study of T900607-Sodium in Previously Treated Patients With Non-Hodgkin's Lymphoma.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "intravenous T900607-sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tularik",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2002-07",
      "completion_date": "2003-03",
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-11-03T15:47:10.999Z",
      "location_count": 5,
      "location_summary": "La Jolla, California • Aurora, Colorado • Chicago, Illinois + 1 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00043459"
    },
    {
      "nct_id": "NCT03698994",
      "title": "Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Recurrent Ependymal Tumor",
        "Recurrent Ewing Sarcoma",
        "Recurrent Glioma",
        "Recurrent Hepatoblastoma",
        "Recurrent Histiocytic and Dendritic Cell Neoplasm",
        "Recurrent Langerhans Cell Histiocytosis",
        "Recurrent Malignant Germ Cell Tumor",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Medulloblastoma",
        "Recurrent Neuroblastoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Osteosarcoma",
        "Recurrent Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Primary Malignant Central Nervous System Neoplasm",
        "Recurrent Rhabdoid Tumor",
        "Recurrent Rhabdomyosarcoma",
        "Recurrent Soft Tissue Sarcoma",
        "Refractory Ependymoma",
        "Refractory Ewing Sarcoma",
        "Refractory Glioma",
        "Refractory Hepatoblastoma",
        "Refractory Histiocytic and Dendritic Cell Neoplasm",
        "Refractory Langerhans Cell Histiocytosis",
        "Refractory Malignant Germ Cell Tumor",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Medulloblastoma",
        "Refractory Neuroblastoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Osteosarcoma",
        "Refractory Peripheral Primitive Neuroectodermal Tumor",
        "Refractory Primary Malignant Central Nervous System Neoplasm",
        "Refractory Rhabdoid Tumor",
        "Refractory Rhabdomyosarcoma",
        "Refractory Soft Tissue Sarcoma",
        "Wilms Tumor"
      ],
      "interventions": [
        {
          "name": "Pharmacokinetic Study",
          "type": "OTHER"
        },
        {
          "name": "Ulixertinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 20,
      "start_date": "2018-11-14",
      "completion_date": "2027-03-30",
      "has_results": true,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-11-03T15:47:10.999Z",
      "location_count": 105,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 82 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03698994"
    },
    {
      "nct_id": "NCT05500222",
      "title": "A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "NASH",
        "Cirrhosis, Liver"
      ],
      "interventions": [
        {
          "name": "Resmetirom",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Madrigal Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 845,
      "start_date": "2022-08-26",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-11-03T15:47:10.999Z",
      "location_count": 96,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Peoria, Arizona + 76 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05500222"
    },
    {
      "nct_id": "NCT03439254",
      "title": "Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Compensated Cirrhosis",
        "Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "Obeticholic acid (10 mg)",
          "type": "DRUG"
        },
        {
          "name": "Obeticholic acid (10 mg to 25 mg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intercept Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 919,
      "start_date": "2017-08-30",
      "completion_date": "2022-09-08",
      "has_results": true,
      "last_update_posted_date": "2023-10-23",
      "last_synced_at": "2026-11-03T15:47:10.999Z",
      "location_count": 120,
      "location_summary": "Dothan, Alabama • Madison, Alabama • Chandler, Arizona + 96 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Madison",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03439254"
    },
    {
      "nct_id": "NCT03492177",
      "title": "A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "selexipag (Uptravi)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actelion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 63,
      "start_date": "2018-07-23",
      "completion_date": "2026-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-03T15:47:10.999Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Iowa City, Iowa • Seattle, Washington",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03492177"
    },
    {
      "nct_id": "NCT05833581",
      "title": "Consistently Assess Signs and Symptom of Heart Failure",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Heart Failure",
        "Heart Failure With Reduced Ejection Fraction",
        "Heart Failure With Preserved Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "New York Heart Association Classification Guide",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Board of Trustees of Illinois State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 104,
      "start_date": "2023-03-17",
      "completion_date": "2024-06-17",
      "has_results": false,
      "last_update_posted_date": "2023-04-27",
      "last_synced_at": "2026-11-03T15:47:10.999Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Normal, Illinois • Lancaster, Pennsylvania",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Normal",
          "state": "Illinois"
        },
        {
          "city": "Lancaster",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05833581"
    },
    {
      "nct_id": "NCT03016819",
      "title": "Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alveolar Soft Part Sarcoma",
        "Leiomyosarcoma",
        "Synovial Sarcoma",
        "Soft-Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "AL3818",
          "type": "DRUG"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        },
        {
          "name": "AL3818 or placebo",
          "type": "DRUG"
        },
        {
          "name": "Midazolam 2 mg for CYP3A4 phenotyping",
          "type": "DRUG"
        },
        {
          "name": "Digoxin (0.25mg)",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin 10 mg tablet.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advenchen Laboratories, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 325,
      "start_date": "2017-08-15",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-25",
      "last_synced_at": "2026-11-03T15:47:10.999Z",
      "location_count": 17,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03016819"
    }
  ]
}